Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma;
Liu, Y, Azizian, NG, Dou, Y, Pham, LV & Li, Y 2019, Journal of Hematology and Oncology, vol. 12, no. 1.

Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index;
Li, Y, Thomas, D, Deutzmann, A, Majeti, R, Felsher, DW & Dill, DL 2019, Scientific reports, vol. 9, no. 1, pp. 16775.

ST2/MyD88 Deficiency Protects Mice against Acute Graft-versus-Host Disease and Spares Regulatory T Cells;
Griesenauer, B, Jiang, H, Yang, J, Zhang, J, Ramadan, AM, Egbosiuba, J, Campa, K & Paczesny, S 2019, Journal of immunology (Baltimore, Md. : 1950), vol. 202, no. 10, pp. 3053-3064.

Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease;
Yang, J, Ramadan, A, Reichenbach, DK, Loschi, M, Zhang, J, Griesenauer, B, Liu, H, Hippen, KL, Blazar, BR & Paczesny, S 2019, JCI insight, vol. 4, no. 5.

Rational Targeted Therapeutics for Double-Hit Lymphoma;
Li, Y 2019, International Journal of Hematologic Oncology.

Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity;
Chen, H-M, van der Touw, W, Wang, YS, Kang, K, Mai, S, Zhang, J, Alsina-Beauchamp, D, Duty, JA, Mungamuri, SK, Zhang, B, Moran, T, Flavell, R, Aaronson, S, Hu, H-M, Arase, H, Ramanathan, S, Flores, R, Pan, P-Y & Chen, S-H 2018, The Journal of clinical investigation, vol. 128, no. 12, pp. 5647-5662.

From proteomics to discovery of first-in-class ST2 inhibitors active in vivo;
Ramadan, AM, Daguindau, E, Rech, JC, Chinnaswamy, K, Zhang, J, Hura, GL, Griesenauer, B, Bolten, Z, Robida, A, Larsen, M, Stuckey, JA, Yang, CY & Paczesny, S 2018, JCI Insight, vol. 3, no. 14.

Leukocyte immunoglobulin-like receptors in human diseases: An overview of their distribution, function, and potential application for immunotherapies;
Zhang, J, Mai, S, Chen, H-M, Kang, K, Li, XC, Chen, SH & Pan, PY 2017, Journal of Leukocyte Biology, vol. 102, no. 2, pp. 351-360.

Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function;
Nam, S, Kang, K, Cha, JS, Kim, JW, Lee, HG, Kim, Y, Yang, Y, Lee, MS & Lim, JS 2016, Journal of Leukocyte Biology, vol. 100, no. 6, pp. 1273-1284.

BIM-mediated apoptosis and oncogene addiction;
Li, Y, Deutzmann, A & Felsher, DW 2016, Aging, vol. 8, no. 9, pp. 1834-1835.
Live Chat Available